Vitiligo is an autoimmune disease that causes depigmentation of the skin, affecting 0.5% to 2% of the population. It can have a significant psychological impact on patients and affects people of all ethnic groups. Treatments include immunosuppressant medications, phototherapy, and laser treatments. Recent research has led to the development of promising new drugs that target the disease’s underlying processes. Conventional treatments, such as corticosteroids and calcineurin inhibitors, are also used. Surgical options, such as cell and tissue transplants, are available for cases that do not respond to other treatments. Patients should discuss their options with their dermatologist and seek information from reliable sources such as the American Academy of Dermatology’s website and the Vitiligo Clinic and Research Center at UMass.
Source link
Innovations in Treating Vitiligo
